Novo Nordisk Raises Sales Outlook on Soaring Demand for Ozempic and Wegovy

Dow Jones2023-10-14

Novo Nordisk stock was rising on Friday after the Denmark-based drug giant raised its sales and operating profit outlook because of strong demand for Ozempic and Wegovy in the U.S.

American depositary receipts of Novo Nordisk climbed 1.96% Friday to $102.14, and the stock hit a new high.

Novo Nordisk said Friday that it now expects 2023 sales growth of between 32% and 38%, an increase from prior expectations of 27% to 33%. The drug maker also said it expects operating profit growth tof between 40% and 46%, up from previous estimates of 31% to 37%.

The company attributed its improved outlook to the strong performance of Ozempic and its cousin drug Wegovy. The demand for these drugs has skyrocketed as patients use them to assist with weight loss. Analysts surveyed by FactSet expect Novo Nordisk to report third-quarter Ozempic revenue of $3.32 billion and Wegovy revenue of $1.07 billion.

Novo Nordisk earlier this week announced that Ozempic showed strong success in a trial for kidney failure in diabetes patients. Because of the results, the company decided to end its study early.

Novo Nordisk stock has jumped 50% this year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

11

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2375947387?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-10-14 08:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2375947387","market":"us","top_or_hot":-1,"title":"Novo Nordisk Raises Sales Outlook on Soaring Demand for Ozempic and Wegovy","media":"Dow Jones","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> stock was rising on Friday after the Denmark-based drug giant raised its sales and operating profit outlook because of strong demand for Ozempic and Wegovy in the U.S.</p><p>American depositary receipts of Novo Nordisk climbed 1.96% Friday to $102.14, and the stock hit a new high.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bf68ae094957151080d635ef0b2c68ad\" tg-width=\"829\" tg-height=\"621\"/></p><p>Novo Nordisk said Friday that it now expects 2023 sales growth of between 32% and 38%, an increase from prior expectations of 27% to 33%. The drug maker also said it expects operating profit growth tof between 40% and 46%, up from previous estimates of 31% to 37%.</p><p>The company attributed its improved outlook to the strong performance of Ozempic and its cousin drug Wegovy. The demand for these drugs has skyrocketed as patients use them to assist with weight loss. Analysts surveyed by FactSet expect Novo Nordisk to report third-quarter Ozempic revenue of $3.32 billion and Wegovy revenue of $1.07 billion.</p><p>Novo Nordisk earlier this week announced that Ozempic showed strong success in a trial for kidney failure in diabetes patients. Because of the results, the company decided to end its study early.</p><p>Novo Nordisk stock has jumped 50% this year.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Raises Sales Outlook on Soaring Demand for Ozempic and Wegovy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Raises Sales Outlook on Soaring Demand for Ozempic and Wegovy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-14 08:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Nordisk stock was rising on Friday after the Denmark-based drug giant raised its sales and operating profit outlook because of strong demand for Ozempic and Wegovy in the U.S.American depositary ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2375947387","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2375947387","pubTimestamp":1697244848,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Novo Nordisk stock was rising Friday after the Denmark-based drug giant raised its sales and operating profit outlook because of strong demand for Ozempic and Wegovy in the U.S.Novo Nordisk  said Friday that it now expects 2023 sales growth of between 32% and 38%, an increase from prior expectations of 27% to 33%. The drug maker also said it expects operating profit growth tof between 40% and 46%, up from previous estimates of 31% to 37%.The company attributed its improved outlook to the strong performance of Ozempic and its cousin drug Wegovy. The demand for these drugs has skyrocketed as patients use them to assist with weight loss. Analysts surveyed by FactSet expect Novo Nordisk to report third-quarter Ozempic revenue of $3.32 billion and Wegovy revenue of $1.07 billion.American depositary receipts of Novo Nordisk climbed 1.6% Friday to $101.77, and the stock was on track to hit a new high, according to Dow Jones Market Data.Novo Nordisk earlier this week announced that Ozempic sho","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"诺和诺德提高了对Ozempic和Wegovy需求飙升的销售前景","themeId":"c5bbfdf5f7964880af97c1d6f417052c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo Nordisk stock was rising on Friday after the Denmark-based drug giant raised its sales and operating profit outlook because of strong demand for Ozempic and Wegovy in the U.S.American depositary receipts of Novo Nordisk climbed 1.96% Friday to $102.14, and the stock hit a new high.Novo Nordisk said Friday that it now expects 2023 sales growth of between 32% and 38%, an increase from prior expectations of 27% to 33%. The drug maker also said it expects operating profit growth tof between 40% and 46%, up from previous estimates of 31% to 37%.The company attributed its improved outlook to the strong performance of Ozempic and its cousin drug Wegovy. The demand for these drugs has skyrocketed as patients use them to assist with weight loss. Analysts surveyed by FactSet expect Novo Nordisk to report third-quarter Ozempic revenue of $3.32 billion and Wegovy revenue of $1.07 billion.Novo Nordisk earlier this week announced that Ozempic showed strong success in a trial for kidney failure in diabetes patients. Because of the results, the company decided to end its study early.Novo Nordisk stock has jumped 50% this year.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":11,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2375947387"}